• Eli Lilly and Co., of Indianapolis, and Boehringer Ingelheim GmbH, of Ingelheim, Germany, presented results from two Phase II studies of their investigational basal insulin analogue LY2605541 at the American Diabetes Association meeting in Philadelphia. In a Type I diabetes trial, patients treated with LY2605541 showed better glycemic control after eight weeks than those who received insulin glargine. The LY2605541 patients also had a 17 percent reduction in their mealtime insulin dose while glargine-treated patients had a 7 percent increase. In a Type II diabetes study, LY2605541 and insulin glargine demonstrated similar improvements in glycemic control. In both studies, patients treated with LY2605541 had statistically significant differences in weight compared with those treated with insulin glargine.